Stock Report

Marksans Pharma Reports Record Q2 FY26 Performance



Posted On : 2025-11-14 08:11:38( TIMEZONE : IST )

Marksans Pharma Reports Record Q2 FY26 Performance

Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) reported the financial results today for the quarter and half-year ended on September 30, 2025.

Mark Saldanha, Managing Director of the Company, said, "Q2FY26 has been a strong quarter for us, with revenues growing 16% sequentially, driven by robust demand across our key markets. The US region recorded solid growth, demonstrating resilience amid macro challenges, supported by stabilizing tariff conditions, timely order book execution, and meaningful traction from new product launches. The UK market also witnessed improved demand and delivered stable results despite continued pricing pressures.

Our EBITDA and PAT grew 44% and 70% quarter-on-quarter, reflecting the benefits of operating leverage.

Looking ahead, we remain optimistic about sustaining this momentum into the second half of the year. Our strategic focus and operational discipline position us well to deliver resilient growth and long-term value for our stakeholders."

Q2FY26 Financial Highlights

- Operating revenue stood at Rs. 720.4 cr., up by 12.2% YoY, attributed to strong traction in the US market, supported by new product launches across the digestive and pain management segments

- Gross profit stood at Rs. 411.8 cr., up by 7.4% YoY, with gross margin of 57.2%

- EBITDA stood at Rs. 144.5 cr., with a margin of 20.1%

- EPS was at Rs. 2.2

H1FY26 Financial Highlights

- Operating revenue stood at Rs. 1,340.4 cr., up by 8.8% YoY

- Gross profit came in at Rs. 770.0 cr., up by 8.1% YoY, with a gross margin of 57.4%

- EBITDA stood at Rs. 244.6 cr. with an EBITDA margin of 18.2%

- EPS was at Rs. 3.5

Shares of Marksans Pharma Limited was last trading in BSE at Rs. 188.30 as compared to the previous close of Rs. 196.60. The total number of shares traded during the day was 99788 in over 1762 trades.

The stock hit an intraday high of Rs. 201.10 and intraday low of 187.00. The net turnover during the day was Rs. 19574160.00.

Source : Equity Bulls

Keywords

MarksansPharma INE750C01026 Q2FY26 H1FY26 ResultUpdate